Edgewise Therapeutics, Inc. - Common Stock, par value $0.0001 per share (EWTX)

Historical Holders from Q1 2021 to Q3 2025

Symbol
EWTX on Nasdaq
Type / Class
Equity / Common Stock, par value $0.0001 per share
Shares outstanding
105,337,747
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
111,964,031
Holdings value
$1,816,272,346
% of all portfolios
0%
Number of holders
171
Number of buys
74
Number of sells
-85
Average buys %
+0%
Average sells %
-0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Edgewise Therapeutics, Inc. - Common Stock, par value $0.0001 per share (EWTX)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
ORBIMED ADVISORS LLC 14.5% $234,894,152 15,252,867 ORBIMED ADVISORS LLC 09 May 2025
RA CAPITAL MANAGEMENT, L.P. 9.9% $169,149,248 10,428,437 RA Capital Management, L.P. 30 Sep 2025
BAKER BROS. ADVISORS LP 6.9% $95,196,398 7,305,940 Baker Bros. Advisors LP 30 Jun 2025
BlackRock, Inc. 5.5% $76,363,411 5,824,866 BlackRock, Inc. 30 Jun 2025
JANUS HENDERSON GROUP PLC 4.7% -10% $80,764,749 -$8,499,572 4,979,331 -9.52% JANUS HENDERSON GROUP PLC 30 Sep 2025
Paradigm Biocapital Advisors LP 5% $72,979,507 4,738,929 Paradigm BioCapital Advisors LP 27 Jan 2025
PERCEPTIVE ADVISORS LLC 4.4% -28.3% $60,458,535 -$22,875,429 4,639,949 -27.5% Perceptive Advisors LLC 30 Jun 2025

Institutional Holders of Edgewise Therapeutics, Inc. - Common Stock, par value $0.0001 per share (EWTX)

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price Investors
2025 Q3 111,964,031 $1,816,272,346 -$102,065,530 $16.22 171
2025 Q2 118,737,861 $1,557,153,070 +$135,315,946 $13.11 177
2025 Q1 105,289,941 $2,320,227,206 +$130,326,516 $22.00 190
2024 Q4 98,918,436 $2,640,722,866 -$78,891,260 $26.70 197
2024 Q3 101,289,495 $2,703,865,523 -$12,073,061 $26.69 174
2024 Q2 101,617,706 $1,830,101,707 +$179,027,088 $18.01 138
2024 Q1 91,602,360 $1,670,777,013 +$311,144,088 $18.24 126
2023 Q4 79,647,397 $871,350,413 +$122,344,417 $10.94 115
2023 Q3 68,438,296 $392,172,292 -$8,215,044 $5.73 84
2023 Q2 69,494,963 $538,802,876 +$23,832,932 $7.75 94
2023 Q1 66,455,672 $443,090,314 -$748,812 $6.67 85
2022 Q4 66,466,915 $594,208,237 +$17,736,112 $8.94 90
2022 Q3 64,390,889 $633,608,275 +$132,537,303 $9.84 92
2022 Q2 50,965,041 $405,682,841 -$30,249,561 $7.96 76
2022 Q1 53,964,373 $523,513,727 +$33,997,944 $9.70 71
2021 Q4 50,239,434 $767,640,710 +$33,441,771 $15.28 56
2021 Q3 48,038,152 $795,758,000 +$3,108,242 $16.60 47
2021 Q2 46,323,514 $984,550,000 +$40,348,386 $21.33 45
2021 Q1 45,681,359 $1,477,378,000 +$1,477,377,994 $32.50 31